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A corrigendum on
Long-term survival in a child with severe encephalopathy, multiple respiratory chain deficiency
and GFM1mutations
by Brito, S., Thompson, K., Campistol, J., Colomer, J., Hardy, S. A., He, L., et al. (2015). Front. Genet.
6:102. doi: 10.3389/fgene.2015.00102
In our article entitled, “Long-term survival in a child with severe encephalopathy, multiple
respiratory chain deficiency and GFM1 mutations,” published in Frontiers in Genetics on 23rd
March 2015 we inadvertently omitted information that the attending paediatrician believes may be
relevant to the case. In the interests of accuracy and completeness we would like to add that the
patient we describe had been receiving treatment with Ubiquinone (20 mg/day), Riboflavin (100
mg/day), Carnitine (500 mg/day), N-acetylcysteine (100 mg/day), and Folinic acid (15 mg/day)
for 6 months prior to inclusion in the report. While there was no obvious improvement in
her condition, equally she has not exhibited any further clinical deterioration since treatment
began. Radiological progression was, however, evident on a cranial MRI performed 5 months
after treatment was initiated. Given the relatively short duration of treatment (approximately 6
months at the time of writing the report) and the neuroradiological progression evident on the
repeat cranial MRI, we consider it unlikely that this vitamin and antioxidant treatment has made a
substantial contribution to the patient’s longer survival.
Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or
financial relationships that could be construed as a potential conflict of interest.
Copyright © 2015 Brito, Thompson, Campistol, Colomer, Hardy, He, Fernández-Marmiesse, Palacios, Jou, Jiménez-Mallebrera,
Armstrong, Montero, Artuch, Tischner, Wenz, McFarland and Taylor. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
